

# SGH Alumni Newsletter

ISSUE 33 | April — June 2021

## INSIDE THIS ISSUE

PG 1  
AROUND THE CAMPUS

---

PG 9  
FELLOWSHIP

---


PG 11  
UPCOMING EVENTS



SGH PGMI  
Postgraduate  
Medical Institute

## NEW APPOINTMENTS

### Key Leadership & Clinical Appointments



**Dr Tan Woei Jen Michelle**  
Head  
Family Medicine & Continuing Care  
*Singapore General Hospital*



**Ms Sandra Koh**  
Chief Operating Officer  
*Changi General Hospital*



**A/Prof Charles Chuah Thaun Heng**  
Director  
Office of Translational Medicine  
*Singapore General Hospital*



**Ms Wai Sue Lea Charity**  
Chief Operating Officer (Designated)  
*SengKang General Hospital*



**Mr Chua Kim Chuan**  
Group Chief Information Security Officer  
*SingHealth*



**A/Prof Rebecca Alexandra Dent**  
Chairman  
Division of Medical Oncology  
*National Cancer Centre Singapore*



**Mr Alson Goh**  
Deputy Group Chief Operating Officer  
Environmental Services, Facilities & Transformation  
*SingHealth*



**A/Prof Ravindran Kanesvaran**  
Deputy Chair  
Division of Medical Oncology  
*National Cancer Centre Singapore*



**Mr Chong Pang Boon**  
Deputy Group Chief Operating Officer  
Security, SGH Campus Integrated Operations & Leadership Development  
*SingHealth*  
  
Chief Operating Officer (Designated)  
*National Cancer Centre Singapore*



**Asst Prof Tham Chee Kian**  
Deputy Chair  
Division of Medical Oncology  
*National Cancer Centre Singapore*



**Mr Tan Tai Kiat**  
Chief Operating Officer  
*SingHealth Community Hospital*  
  
Chief Operating Officer  
Environmental Sustainability  
*SingHealth*



**Ms Amber Yeong Hor Kwan**  
Chief Operating Officer (Designated)  
*National Heart Centre Singapore*



**A/Prof Adrian Koh**  
Group Director  
Education (Graduate)  
*SingHealth*



**Mr Jim Gu**  
Chief Operating Officer  
*Singapore National Eye Centre*



**A/Prof Goh Su-Yen**  
Head  
SingHealth Duke-NUS Diabetes Centre  
*SingHealth*

---

## AWARDS RECIPIENTS

---

### CLOSE TO 7,000 STAFF FROM ACROSS THE HEALTHCARE SECTOR HONoured FOR CONTRIBUTIONS IN FIGHTING THE COVID-19 PANDEMIC

Close to 7,000 staff from across the healthcare sector honoured for contributions in fighting the COVID-19 pandemic



**29 March 2021** – The Singapore Health Quality Service Awards was held today at the Ngee Ann Kongsi Auditorium, Academia on Singapore General Hospital (SGH) Campus with Minister for Health, Mr Gan Kim Yong, as the Guest-of-Honour.

Now into its 11th year, the annual Awards organised by the SingHealth Duke-NUS Academic Medical Centre since 2011 is Singapore’s first dedicated platform to honour outstanding healthcare professionals who have delivered quality care and service to patients.

This year’s Awards is a special COVID-19 edition themed “Celebration of Unity”, which celebrates close to 7,000 healthcare professionals and partners from 38 public and private healthcare institutions, community hospitals as well as agencies from the Community Care sector who have contributed significantly in the nation’s fight against COVID-19. This is a record number of winners in the history of the Awards.

6860 individuals were presented the Hero Awards, while 17 top winners from the Clinician, Nursing, Allied Health, Administration, Ancillary and ILTC (Intermediate and Long-Term Care) categories received SuperHero Awards for their outstanding contributions during the pandemic. Three teams who championed exceptional and innovative initiatives that demonstrated impactful results and benefits to patients, staff and the public were recognised with the Best Team Award.

Award recipients were selected based on stringent criteria including their contributions in enhancing the quality of healthcare delivery during the COVID-19 pandemic, as well as testimonials of acts of service that went the extra mile during this challenging time.

Read more at: <https://www.sgh.com.sg/news/awards/close-to-7-000-staff-from-across-the-healthcare-sector-honoured-for-contributions-in-fighting-the-covid-19-pandemic>



## NEW DEVELOPMENTS

## THE SHOW MUST GO ON...RAIN OR SHINE



With less than 4 hours to go before the start of [our SGH200 celebration event in the SGH Bicentennial Garden](#), the sky opened up. But the SGH can-do spirit saved the day, and the show went on without a hitch.

Amidst crashing thunder, torrential rain flooded the SGH Bicentennial Garden. In less than four hours, VIP guests, including the Deputy Prime Minister, were going to plant trees for the Rooted in Excellence event, to open the garden and launch the SGH200 celebrations on an outdoor stage.



The entrance to the SGH Museum, where the formal proceedings were going to take place, was also inundated. Miraculously, the downpour stopped just as our guests started arriving and 20 minutes before the arrival of Deputy Prime Minister Mr Heng Swee Keat, our Guest of Honour. After a quick huddle with our Projects team and Environmental Services

colleagues, we made the call to proceed with a scaled-down tree planting event, after the formal proceedings inside the museum.

Inside, everything was snug and dignified and the programme proceeded without a hitch. The museum was not the natural first choice for the venue because the space constraints posed great challenges to adhere to safe management measures. Nobody would have guessed the weeks and hours we had spent counting and recounting the number of people allowed inside. “One more camera man? Then the stage manager must go out.” To be sure, we also measured and marked every chair, and every position for every person on stage without over-compromising the experience for the guests.

In the end, DPM Mr Heng was able to plant the first tree in the Bicentennial Garden, to mark its opening, and to allow us to most aptly celebrate to our theme of “Rooted in Excellence.” This official photo also did not happen by chance – we had planned it down to the details of who is to stand where, and making sure Bowyer Block forms the background. And the giant green sticker on the floor was part of the plan to make sure the VIPs were standing safely distanced if the speeches had been delivered in the garden.

We did not allow the restrictions on the size of the gathering to stop us from including our staff and partners as guests at the very special event. We simply went online! In the end, more than 800 staff and other guests such as leaders of other healthcare institutions joined us for the event which was streamed live. They also ‘planted’ a virtual tree of their own, and enjoyed a 360-degree gallery view of the newly refurbished SGH Museum.

You can visit the SGH Museum when it is opened at the end of April, as a thoroughfare from SGH Block 4 to SGH Diabetes and Metabolism Centre. Please take care of the exhibits which have been lovingly restored and put on display. Remember not to lean against the columns – they are 95-years-old, as the SGH Museum is housed in a national monument first completed in 1926. The Bicentennial Garden will be opened later in the year, when it is more mature.

Happy SGH200 everyone! May the SGH spirit continue to sparkle.

Read more at: <https://www.sgh.com.sg/news/lighternotes/the%20show%20must%20go%20on%20rain%20or%20shine>

Source: LighterNotes (SGH)

## NEW DEVELOPMENTS

### SINGHEALTH DUKE-NUS AMC AND CORDLIFE PARTNER TO ADVANCE STEM CELL TECHNOLOGY TO FIRST IN MAN CLINICAL TRIAL IN SINGAPORE

*First-of-its-kind in Singapore, the clinical trial will test a technology that enables specific cell therapy products to be manufactured for use in patients.*

**11 May 2021**– Institutes and centres under the SingHealth Duke-NUS Academic Medical Centre (AMC) are joining hands together with Singapore’s first private cord blood bank, Cordlife Group Limited (Cordlife), to test a novel technology that expands the number of blood-forming stem cells from stored umbilical cord blood (UCB) in a first-in-man study in Singapore. This is the first time a home-grown UCB cell therapy is being tested on humans. The technology has the potential to increase treatment options for patients suffering from blood cancers or blood-related conditions.

One of the most effective treatments for patients with blood cancers, such as leukaemia, lymphomas and hereditary blood-related conditions, such as thalassaemia is to transplant haematopoietic stem and progenitor cells (HSPCs) harvested from UCB. However, the current applications of HSPCs are limited as the number of HSPCs that can be harvested from a UCB is typically low, yielding few useable units for adult transplant patients. Administering a UCB with low cell count often results in slower recovery and greater susceptibility to fatal infections.

The technology to be tested in this trial uses a laboratory-synthesised compound called C7 for ex-vivo expansion of HSPCs, which, in turn, enables specific cell therapy products to be manufactured for use in patients.

“Based on pre-clinical studies, C7 appears to be able to expand banked cord blood stem cells to generate sufficient quantity for adult transplant patients while maintaining their quality,” said Professor William Hwang from Duke-NUS’ Cancer and Stem Cell Biology Programme. Prof Hwang, who heads the SingHealth Duke-NUS Cell Therapy Centre, is also medical director of the National Cancer Centre Singapore (NCCS) and a senior consultant with the Department of Haematology at Singapore General Hospital (SGH). As a haematologist, he has dedicated his career caring for patients with blood cancers, one of the most common causes of cancer deaths, accounting for approximately 720,000 deaths globally every year. This accounts for 7 per cent of all cancer deaths, according to GLOBOCAN 2018 statistics. Prof Hwang and his laboratory team, together with researchers from NUS, discovered C7’s ability to increase the numbers of blood-forming stem cells from UCB. “The effect of C7 on blood stem cells also seems to be better than anything else we have used in other clinical trials for cord blood expansion.”

Leading this clinical trial is Dr Francesca Lim, a consultant at SGH’s Department of Haematology and SingHealth Duke-NUS Blood Cancer Centre, who said, “The ability to expand UCB HSPCs for clinical use provides an opportunity to overcome cord blood transplants’ short-term disadvantages of low total cell dose. This is an important step forward to improve treatment outcomes for transplant patients, especially those who rely on umbilical cord blood as the only source of grafts due to the lack of a fully matched bone marrow or peripheral blood stem cells.”

Duke-NUS and SingHealth manage the patent for the application of C7 in expanding UCB HSPC through their Joint Centre for Technology and Development (JointCTeD), which sealed the industry partnership with Cordlife to enable this clinical trial.

Associate Professor Chris Laing, Senior Associate Dean for Innovation and Entrepreneurship at Duke-NUS, said, “This technology has the potential to significantly improve patients’ treatment outcome. We are privileged to work with the inventors and industry partners to ensure this promising technology continues to advance. This landmark clinical trial – the first clinical trial of a Singapore stem cell expansion technology from UCB – is an example of our commitment in translating cutting-edge innovations into better patient care.”


In preclinical studies, UCB treatment has been shown to be immunologically superior compared with other cell and gene therapies given its greater tolerance for human leucocyte antigen mismatch, reduced graft versus host disease and lower incidence of relapse.

“We are very excited to be a part of this revolutionary clinical trial in Singapore. This project is significant to us because different players across the ecosystem are coming together to create a paradigm shift in cellular therapies. Once the HSPC expansion technology is proven safe and effective, more patients can rely on cord blood for treatment,” said Ms Tan Poh Lan, Group CEO and Executive Director of Cordlife.

Read more at: <https://www.sgh.com.sg/news/singhealth-duke-nus-amc-and-cordlife-partner-to-advance-stem-cell-technology-to-first-in-man-clinical-trial-in-singapore/singhealth-duke-nus-amc-and-cordlife-partner-to-advance-stem-cell-technology-to-first-in-man-clinical-trial-in-singapore>

## NEW DEVELOPMENTS

## LANDMARK STUDY LAUNCHED TO DETECT LIVER CANCER EARLY IN SINGAPORE



Quantitative MR images of the liver from six patients presenting with liver cancer produced by Perspectum's LiverMulti-Scan which will be used in a new study led by National Cancer Centre Singapore. Image credit Mole DJ et al. Plos One. 2020;15(12)e0238568

- Only 20% of primary liver cancer or hepatocellular carcinoma (HCC) are diagnosed at an early stage, which makes early detection an urgent, unmet healthcare need.
- Study aims to develop more accurate diagnostics for early HCC, an AI algorithm to predict an individual's risk of developing HCC, and discover novel molecular targets to prevent the development of HCC.
- Study aims to recruit 2,000 participants at high risk of developing HCC from six healthcare institutions and eight polyclinics across Singapore.

**3 May 2021** – A first of its kind cohort study on patients at high risk of developing primary liver cancer also known as hepatocellular carcinoma (HCC), has been launched to diagnose HCC more accurately at an earlier stage and to predict an individual's likelihood of developing the cancer. HCC is the sixth most common cancer in the world but the third most common cause of cancer deaths globally<sup>1</sup>. In Singapore, HCC is the third and fourth most common cause of cancer deaths, amongst males and females respectively<sup>2</sup>. While potentially curative treatment is possible with early diagnosis, only 20% of HCC cases are detected at a stage where cure is possible. This investigator-initiated multi-centre study led by the National Cancer Centre of Singapore (NCCS) called **EarLy DETection of HCC: miRNA, microbiome and imaGing biomArkers in the evolution of chroNiC livEr Disease in a high-risk prospective cohort (ELEGANCE)**, addresses this urgent, unmet need for individuals at high risk of developing HCC.

While individuals at high risk of developing HCC are well defined clinically as those with pre-existing liver cirrhosis, chronic viral hepatitis and/or fatty liver, there are currently no validated diagnostic, predictive and prognostic biomarkers for HCC, making early diagnosis challenging. Identifying such biomarkers would greatly improve patient outcomes. Currently, emerging data suggest that the evolution of chronic liver disease into HCC may be reflected by changes in the stool (microbiome), blood and urine (metabolome). An AI algorithm that leverages MRI imaging parameters may also be able to predict an individual's risk of developing HCC by offering personalised prediction.

The ELEGANCE study will enrol patients at high-risk of developing HCC to deliver robust scientific data with the aim of developing more precise clinical tools to diagnose HCC at an early stage and predict which individuals are at highest risk. In addition, the study will highlight how the microbiome and metabolome changes with disease development and identify potential therapeutic targets that may slow disease progression and reduce the risks of developing cancer.

Read more at: <https://www.sgh.com.sg/news/research/landmark-study-launched-to-detect-liver-cancer-early-in-singapore>



## NEW DEVELOPMENTS

### CLINICAL TRIAL EXAMINES USE OF TRADITIONAL CHINESE MEDICINE TO IMPROVE CANCER SURVIVORS' QUALITY OF LIFE

Some of the herbs used in the modified TCM formula in the HERBAL trial, conducted at the National Cancer Centre Singapore. Credit Singapore Thong Chai Medical Institution.

Cancer-related symptoms or treatment-related side effects such as cancer-related fatigue can affect quality of life

Trial will use Traditional Chinese Medicine as a therapy for cancer-related fatigue

The National Cancer Centre Singapore-led trial which is currently recruiting eligible participants, aims to enrol and administer treatment to 80 participants over two years

Singapore, 22 April 2021 – The National Cancer Centre Singapore (NCCS) has started a clinical trial to examine the use of Traditional Chinese Medicine (TCM) in countering cancer-related symptoms or side effects of cancer treatment to improve cancer survivors' quality of life. With advances in cancer diagnosis and treatment, cancer survivorship has improved significantly, but cancer survivors often experience a range of cancer-related and post-treatment side effects such as cancer-related fatigue.

Cancer-related fatigue (CRF) refers to a distressing and persistent sense of physical, emotional and/or cognitive tiredness which is a side-effect of cancer or anti-cancer treatments. CRF is frequently experienced by cancer survivors and can interfere with their daily functioning. The HEalth-Related quality of life-intervention in survivors of Breast and other cancers experiencing CRF using TraditionAl Chinese Medicine, or the HERBAL trial, aims to evaluate the benefit of using TCM to manage side-effects experienced by cancer survivors.

Current recommended treatments for CRF include non-pharmacological management such as exercise, cognitive behavioural therapy and patient education. Pharmacological therapies are still under investigation but have shown limited efficacy so far. This is partly because the biological mechanism underlying CRF has not been fully established.

“As the recommended management of CRF is limited, both in scope and efficacy, many patients continue to have persistent symptoms. More research in this arena is required and culturally appropriate interventions should be tailored to each individual patient. We observe many of our patients seeking adjunctive therapies, such as TCM, to manage their symptoms,” said Dr Tira Tan, Principal Investigator of the HERBAL trial and Consultant in the Division of Medical Oncology, NCCS. Scientific data validating the benefits of TCM is sparse which prompted a team of investigators to design the HERBAL trial.

#### Conducting a first-of-its-kind TCM trial to manage side effects of cancer treatment

The HERBAL trial will evaluate the use of an investigational modified TCM formula known as Xiang Bei Yang Rong Tang (香贝养荣汤 or XBYRT) in alleviating CRF. The formula used in the research study was developed by study Co-Investigator Prof Alexandre Chan, Visiting Professor, Oncology Pharmacy, NCCS in consultation with TCM physicians from Singapore Thong Chai Medical Institution (STCMI).

In TCM literature XBYRT is believed to be able to augment qi, nourish the blood, improve appetite and calm the mind with the aim of alleviating CRF in cancer survivors.


Read more at: <https://www.sgh.com.sg/news/research/clinical-trial-examines-use-of-traditional-chinese-medicine-to-improve-cancer-survivors-quality-of-life>



## NEW DEVELOPMENTS

## WHEN THE GRAFT FOR DIALYSIS FAILS – SGH STUDIES NEW TREATMENT OP-

When the graft for dialysis fails – SGH studies new treatment option



**24 March 2021** – Besides the thrice-weekly haemodialysis sessions in a dialysis centre, 70 per cent of patients with a history of blocked graft have to visit the hospitals to unclog it every six months. The graft, typically in the arm, is used to access patient's blood vessels during dialysis to remove waste products and extra fluid. Without the access, consequences can be fatal.

To explore another possible treatment option that can keep the graft viable for a longer duration, a team of clinicians from Singapore General Hospital (SGH) conducted a pilot study using an angioplasty balloon coated with sirolimus, which has been used successfully to prevent repeated narrowing of the coronary artery.

"A blocked graft is one of the commonest causes of hospitalisation in patients on haemodialysis. Understandably, it can be frustrating for them as the need for repeated treatment to salvage a failing graft is on top of their thrice-weekly dialysis sessions. Imagine the extra time and cost that they had to incur as a result," said Associate Professor Tan Chieh Suai, Head and Senior Consultant, Department of Renal Medicine, SGH. Prof Tan is also the senior author of the study.

Together with his colleagues from the Departments of Renal Medicine, Vascular Surgery, and Vascular and Interventional Radiology, the team recruited 20 patients between October 2018 and October 2019 for the study. The patients first underwent a procedure to clear the blockages, followed by an angioplasty where a catheter with a sirolimus-coated balloon at the end was inserted into the affected area. Once in place, the drug-coated balloon was inflated to transfer the drug to the interior walls of the graft and blood vessel joint. The balloon is then deflated and removed. Patients remained awake throughout the 1-hour procedure performed under local anaesthesia.

The team discovered that at six months, 50 per cent of the studied patients needed another repeat procedure. This was 20 per cent less than those treated with current treatment options such as insertion of a stent, which can be costly, a plain balloon, or a balloon coated with chemotherapy drug, paclitaxel.

Read more at: <https://www.sgh.com.sg/news/patient-care/when-the-graft-for-dialysis-fails-sgh-studies-new-treatment-option>



## NEW DEVELOPMENTS

### MOVING TOWARDS ZERO ASTHMA EMERGENCIES



*Under the A-CARE programme, Senior Staff Nurse Jenneth Leow provides asthma counselling and education on inhaler use to patients like Ms Katrina Tan (right), who was unaware of the severity of her symptoms until she was admitted to SGH's ED in 2019 for a severe asthma attack.*

A pilot programme, which incorporated asthma counselling into the patient journey at the Emergency Department, brought about improved asthma management and outcomes.

#### Capacity

When patients do not understand their asthma or how to care for their condition, they find themselves seeking treatment — often repeatedly — at the emergency departments (ED) for severe symptoms, such as breathlessness and chest tightness.

Severe asthma attacks can be life-threatening. Of 376 patients with life-threatening asthma who were admitted to the intensive care units of four restructured hospitals, 47 died during admission, a 2011-2015 study found. Severe asthma attacks also tend to occur at night, when temperatures drop.

To reduce ED visits and hospital admissions, an asthma specialist nurse has been included in Singapore General Hospital's (SGH) ED night team under a pilot programme called Asthma-COPD (chronic obstructive pulmonary disease) Afterhours Respiratory Nurse at Emergency, or A-CARE.

“When patients come to the ED with an acute asthma attack, the ED physician performs initial treatment. When their condition stabilises, they are transferred to the short-stay unit for up to 23 hours. That is when the A-CARE nurse comes into the picture,” said Dr Kenneth Tan, Head and Senior Consultant, Department of Emergency Medicine, SGH.

Asthma nurses have been part of SGH's ED team for over 10 years, but this is the first time that one has been placed on night duty. Asthma nurses provide important clinical support to ED doctors, assessing patients' overall conditions, recommending inhalers, and arranging postdischarge follow-up.

Like other chronic medical conditions, asthma requires regular and long-term treatment and management, said Associate Professor Mariko Koh, Senior Consultant, Department of Respiratory and Critical Care Medicine, SGH.

“Patients do not realise that asthma, like diabetes and high blood pressure, is a chronic condition that requires long-term care,” said Prof Koh, adding that regular outpatient follow-up and management can help cut down on readmissions as patients' asthma stabilises.

Read more at: <https://www.sgh.com.sg/news/singapore-health/moving-towards-zero-asthma-emergencies>

*Source: Singapore Health*

### WEEKLY LUNCHTIME Q+A SESSION WITH GPs

SGH Patient Liaison Services (PLS) department has started the Weekly Lunchtime Q+A Session with GPs in end of February 2021 as part of SGH continuous engagement with GPs. The sessions help to address some of the burning questions pertaining to patient's medical care. Together with the support from SGH Postgraduate Medical Institute, PLS piloted the collaboration with specialists from Department of Orthopedic Surgery and Otorhinolaryngology and will continue to bring in other disciplines to the sessions. We welcome you to join our Q&A session on every Wednesday at 1pm to 2pm.

Please click on the below link (internet access required) for more information on the upcoming sessions and to register & submit your questions:

[https://ihis.zoom.us/meeting/register/tjclfuChqDwiHtT-DKNCXwQz7h2iC\\_u\\_WrLx](https://ihis.zoom.us/meeting/register/tjclfuChqDwiHtT-DKNCXwQz7h2iC_u_WrLx)

## FELLOWSHIPS & INTERNATIONAL COLLABORATIONS

### Dr Mohammed Ali Alalsaidiessa from Iraq shares his fellowship experience in SGH, Department Vascular & Interventional Radiology (VIR)

#### What was your impression of Singapore's healthcare industry?

Amazing, I was impressed by the facilities and the advanced healthcare services.

#### Are there any differences compared to the healthcare industry in your country?

Yes. Our country suffered a lot from the continuous warfare and instability. This have affected all aspects of life including the health services. In addition, VIR is a new growing medical speciality in Iraq, as compared to Singapore.



*Dr Mohammed Ali Alalsaidiessa during his fellowship programme with department Vascular & Interventional Radiology*

#### Why did you choose to apply to Singapore/SGH for your attachment?

There are two main reasons for my choice. Firstly, I did my Fellow of the Royal College of Radiologists examinations in Singapore, and I was impressed of the country. Secondly, the first language in Singapore is English.

#### Did you face any difficulties (e.g. culture, language) during your attachment? What were they?

Yes, the most difficult thing was missing my parents, family and being alone for the first time in my life. My family visited many times during my fellowship. The Singaporean English slang was slightly different from the regular spoken English from other parts of the world, and it took me around two months to get used to.

#### During your attachment, what was a 'typical' day like?

I woke up early to have my breakfast and then go to hospital. Our day started with a lecture or meeting at 7:30am with the consultants and staff in VIR. At 8:30am we proceeded to the VIR suites and started with a variety of cases and we finished around 6 pm. Sometimes we have extended duties that may extend to midnight or later. There are an average of two extended duties per week. After work, I returned to my apartment and read up on topics about VIR.

#### What were your learning experiences?

I came to SGH with zero skills in VIR. After a year in SGH, I am filled with knowledge and have my plans set for my patients.

#### How has the attachment make an impact on you?

I learned a lot from the attachment. Aside from VIR procedures, I also learned skills on co-operating with colleagues, respecting the patients and help them cure.

#### Do you have any interesting/memorable experience during your attachment that you would like to share?

It was a nice opportunity to be trained in a developed country/hospital.

## FELLOWSHIPS & INTERNATIONAL COLLABORATIONS



Dr Mohammed Ali Alalsaidiessa (2nd from the right)  
(Photos were taken before the issuance of government advisories on COVID-19)

### What did you enjoy most during your attachment?

I enjoyed the availability of the huge variety of procedures and the group of friendly consultants in VIR. It was a great opportunity to learn from each consultant, learning the procedure of his way. I also enjoyed that everyone in SGH worked as a team to help their patients.

### Would you recommend SGH to interested fellows? Why?

Sure, for many reasons. It is a very good place to learn VIR, all the facilities are readily available, a variety of consultants and VIR procedures, etc.

### How would you describe your Hospital Management Training experience in 3 words?

Amazing, Useful, Fulfilling.

*Photo Credits: Mohammed Ali Alalsaidiessa*

## WELCOME!

We welcome our new Alumni Member:

| Name                | Specialty           | Country     |
|---------------------|---------------------|-------------|
| Dr Pantas Jim Bryan | Orthopaedic Surgery | Philippines |
| Dr Jerry Tan        | Anaesthesia         | Singapore   |



## TELL US WHAT YOU WANT!

We are always looking for ways to improve and engage our alumni members. If you have any suggestions or ideas for newsletter contents or alumni events, know anyone who would like to contribute to the newsletter, please let us know! Email your suggestions and contributions to [alumni@sgh.com.sg](mailto:alumni@sgh.com.sg)



# UPCOMING EVENTS

NEW

## WEEKLY WEDNESDAY LUNCHTIME Q+A SESSION WITH GPs

Registration Link: [https://ihis.zoom.us/meeting/register/tJclfuChqDwiHtT-DKNCXwQz7h2iC\\_u\\_WrLx](https://ihis.zoom.us/meeting/register/tJclfuChqDwiHtT-DKNCXwQz7h2iC_u_WrLx)

## JULY 2021

**24TH**

### **“Early Childhood Adversities: Implications for practice”**

Presented by KKH

Registration Link: <https://www.sgh.com.sg/events/education/early-childhood-adversities-implications-for-practice-webinar>

## August 2021

**3RD**

### **Head & Neck Surgery GP Webinar**

Presented by SGH Department of Head & Neck Surgery Dept

Registration Link: [https://ihis.zoom.us/webinar/register/WN\\_dbTcfF0oTsupDeDvvdXNuA](https://ihis.zoom.us/webinar/register/WN_dbTcfF0oTsupDeDvvdXNuA)

**14TH**

### **Endocrinology Update**

Presented by SGH Department of Endocrinology

Registration  
Opening Soon

**21ST**

### **SGH & SNEC PF Webinar on Thyroid Eye Disease**

Presented by SNEC & SGH Department of Endocrinology

Registration  
Opening Soon

## September 2021

**14TH**

### **Pain Management GP Webinar**

Presented by SGH Pain Management Department

Registration  
Opening Soon

Please refer to our website <https://www.sgh.com.sg/pgmi> for events updates.



*Photo Credits: [Islamic vector created by freepik](#)*

***SGH — PGMI***

***Wishes all Alumni Members***

***Happy Hari Raya Puasa!***

**SGH ALUMNI NEWSLETTER**

c/o SGH Postgraduate Medical Institute  
20 College Road,  
Academia, Level 2,  
Singapore 169856  
+65 6576 7658

**Advisory Board**

Prof Hwang Nian Chih  
Ms Emily Lim

**Editor**

Mr Lin JiaHui

Please visit [https://www.sgh.com.sg/pgmi/sgh\\_alumnus/Pages/SGH-Alumni-e-Newsletters.aspx](https://www.sgh.com.sg/pgmi/sgh_alumnus/Pages/SGH-Alumni-e-Newsletters.aspx) for the e-newsletter